CervoMed

#药闻简讯# 2025年10月8日——专注于开发治疗与年龄相关的神经系统疾病的临床阶段公司$CervoMed(CRVO)$ 今日宣布了其 Phase 2b RewinD-LB 试验的更多数据，进一步展示了 Neflamapimod 作为治疗路易体痴呆（DLB）的潜力。

#药闻简讯# $CervoMed(CRVO)$ 宣布RewinD-LB试验扩展阶段的32周数据，显示Neflamapimod对Lewy体痴呆患者临床进展的持续抑制作用，以及与神经退行性变相关的关键血浆生物标志物水平的降低。

$CervoMed(CRVO)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001437749-25-024847  Act: 34  Size: 158 KB 网页链接

$CervoMed(CRVO)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001415889-25-022464  Act: 34  Size: 18 KB 网页链接

$CervoMed(CRVO)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001415889-25-022009  Act: 34  Size: 12 KB 网页链接

$CervoMed(CRVO)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001437749-25-030719  Act: 34  Size: 207 KB 网页链接

$CervoMed(CRVO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001437749-25-025570  Act: 34  Size: 5 MB 网页链接

$CervoMed(CRVO)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001437749-25-023646  Act: 34  Size: 225 KB 网页链接

$CervoMed(CRVO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001437749-25-025814  Act: 34  Size: 300 KB 网页链接

$CervoMed(CRVO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001437749-25-030705  Size: 3 KB 网页链接

$CervoMed(CRVO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-25-030707  Size: 5 KB 网页链接